...(4×), FGFR2 (3×), ALK (2×), RET (2×), NTRK1 (1×), RASGRP1 (1×), and ROS1 (1×). Some of the affected proteins are direct interaction partners of KRAS (RASGRP1, BRAF, RAF1), suggesting that the corresponding fusion proteins might activate the same pathway as oncogenic KRAS. Indeed, a statistical...